KOSDAQ intraday 800line breached; D&D Pharmatech surges
The KOSDAQ 2026 year 7 month 8 day fell below the 800line intraday, retreating to levels from 10 months ago. During the same period, D&D Pharmatech's share price surged on news that its global partner had begun a contrast-agent clinical 2 trial, while SD Biosensor and Cheongdam Global disclosed, respectively, their entry into public procurement for tuberculosis diagnostic products and an expansion of brands participating in pop-up events and fairs.
Get free 디앤디파마텍 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
The KOSDAQ fell below the 2026 year 7 month 8 day intraday, retreating to levels from 800 months ago. The intraday decline reached the 10% range.4},
D&D Pharmatech's global technology-transfer partner 2026 year 7 month 8 day disclosed that it had begun phase 2 of a clinical trial for a contrast agent. Price movements were detected in related stocks immediately before and after the disclosure.
D&D Pharmatech 2026 year 7 month 7 day was reported to have seen its share price surge even as the KOSDAQ stood at its yearly low. The company's disclosure of clinical progress was cited as the reason behind the surge.
SD Biosensor 2026year 7month 8day announced that it would supply tuberculosis diagnostic products to the global public procurement market. The plan to enter the public procurement market and the product range were specified.
Cheongdam Global 2026year 7month 8day announced that it would expand the brands participating in global pop-up and trade fair projects. The company announced plans related to expanding the participating brands.
These disclosures were concentrated on the same date. The market showed mixed movements as intraday declines and favorable disclosures from individual stocks emerged simultaneously that day.